TAS2R30

Across TCGA pan-cancer cohorts, TAS2R30 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TAS2R30 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TAS2R30 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TAS2R30 expression acts as an unfavorable survival marker.

HNSC and DLBC are the cancer types where TAS2R30 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.156	0.751	<.001	48	view →
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	24	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

TAS2R30–HNSC (OS)

Open the HNSC breakdown →